Edward M. Kaye MD - 14 Aug 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
14 Aug 2025
Net transactions value
$0
Form type
4
Filing time
18 Aug 2025, 20:23:23 UTC
Previous filing
16 Jul 2025
Next filing
20 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kaye Edward M. MD Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 18 Aug 2025 0001522780

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +26,250 +19% $0.000000 165,596 14 Aug 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Performance Stock Units Award $0 +52,500 $0.000000 52,500 14 Aug 2025 Common Stock 52,500 Direct F1, F2, F3
transaction STOK Performance Stock Units Options Exercise $0 -26,250 -50% $0.000000 26,250 14 Aug 2025 Common Stock 26,250 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit represents a right to receive one share of the Issuer's common stock.
F2 This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.
F3 Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.